The extremely poor prognosis and lack of effective treatments for glioblastoma (GBM) remains a significant public health issue. While traditional MRI techniques are valuable in determining GBM response to common anti-neoplastic therapies, novel treatments including immunotherapies, anti-angiogenic agents, or therapies that alter tumor metabolism may result in radiographic changes that are challenging to differentiate from non- responsive or growing tumor. Therefore, the primary goal of the Neuro-Imaging Core (NIC) will be to provide advanced MRI and PET imaging support with established reliability and consistency to SPORE project investigators for their respective projects. Specifically, the NIC will use quantitative ?MRI and ?PET for pre- clinical imaging (Aim 1) and state-of-the-art MR and PET imaging acquisition, advanced post-processing, and novel analysis tools for clinical imaging of patients in novel clinical trials (Aim 2). Hence, this Core will add value to the overall SPORE by helping investigators to better understand the in situ metabolic, physiologic, and traditional radiographic changes within the brain and tumor in order to address specific objectives of each of the UCLA Brain Cancer SPORE projects. Another main goal of the NIC is to understand the link between metabolic and/or physiologic imaging and tumor biology in order to reliably delineate treatment response versus recurrent tumor (Aim 3), which in turn will facilitate the direct translation of new MR-PET companion biomarkers/techniques to the clinic for the evaluation of treatment response in ongoing and new therapeutic clinical trials resulting from the SPORE projects and cores.

Public Health Relevance

Core 2: Neuro-Imaging Core (NIC) NARRATIVE Standard radiographic interpretation of the therapeutic benefit of new treatment paradigms for glioblastoma remains a significant scientific and clinical challenge. Therefore, the purpose of the Neuro-Imaging Core (NIC) is to provide reliable/consistent standard and advanced pre-clinical and clinical imaging support for all projects in the UCLA SPORE in Brain Cancer in order to non-invasively stratify for treatment prognosis and to quantify treatment-related changes in tumor biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA211015-02
Application #
9543449
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Levin, Victor A; Ellingson, Benjamin M (2018) Understanding brain penetrance of anticancer drugs. Neuro Oncol 20:589-596
Ferguson, Sherise D; Zhou, Shouhao; Huse, Jason T et al. (2018) Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol 77:437-442
Ellingson, Benjamin M; Salamon, Noriko; Woodworth, Davis C et al. (2018) Reproducibility, temporal stability, and functional correlation of diffusion MR measurements within the spinal cord in patients with asymptomatic cervical stenosis or cervical myelopathy. J Neurosurg Spine 28:472-480
Kuo, Eric J; Sho, Shonan; Li, Ning et al. (2018) Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma. JAMA Surg 153:52-59
Kirsch, David G; Diehn, Max; Kesarwala, Aparna H et al. (2018) The Future of Radiobiology. J Natl Cancer Inst 110:329-340
Laks, Dan R; Oses-Prieto, Juan A; Alvarado, Alvaro G et al. (2018) A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma. Neuro Oncol 20:764-775
Magaki, Shino; Tang, Zhaoyi; Tung, Spencer et al. (2018) The effects of cerebral amyloid angiopathy on integrity of the blood-brain barrier. Neurobiol Aging 70:70-77
Omuro, Antonio; Vlahovic, Gordana; Lim, Michael et al. (2018) Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol 20:674-686
Magaki, Shino D; Williams, Christopher K; Vinters, Harry V (2018) Glial function (and dysfunction) in the normal & ischemic brain. Neuropharmacology 134:218-225
Woodworth, Davis C; Holly, Langston T; Mayer, Emeran A et al. (2018) Alterations in Cortical Thickness and Subcortical Volume are Associated With Neurological Symptoms and Neck Pain in Patients With Cervical Spondylosis. Neurosurgery :

Showing the most recent 10 out of 91 publications